Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer (pyruvate)

A Pilot Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) to Detect High Grade Localized Prostate Cancer

This pilot clinical trial studies how well magnetic resonance spectroscopic imaging (MRSI) with hyperpolarized carbon C13 pyruvate works in finding prostate cancer that exhibits poorly differentiated or undifferentiated cells (high-grade) and that is restricted to the site of origin, without evidence of spread (localized) in patients undergoing radical prostatectomy. Diagnostic procedures, such as MRSI with hyperpolarized carbon C13 pyruvate, may aid in the diagnosis of prostate cancer and in discriminating high-grade from low-grade prostate cancer and benign adjacent prostate tissue

Study Overview

• Status: Recruiting
• Conditions: Prostate Cancer
• Intervention / Treatment: Procedure: Magnetic Resonance Spectroscopic Imaging; Drug: Hyperpolarized 13C,15N2-urea; Drug: Pyruvate (13C)

Detailed Description

PRIMARY OBJECTIVE:

I. To investigate the association between hyperpolarized (HP) pyruvate-to-lactate conversion (kPL) and HP urea perfusion with histologic grade of prostate cancer, including benign prostate tissue, low grade disease (primary Gleason score < 4), and high grade (primary Gleason score >= 4) prostate cancer.

SECONDARY OBJECTIVES:

I. Safety. II. To determine the optimal cut-off value of peak lactate to pyruvate ratio (lac/pyr), lac/pyr area under the curve (AUC), 13C pyruvate to lactate (kPL) rate, urea AUC, and urea transfer constant (ktrans) on magnetic resonance imaging (MRI) that accurately detects primary Gleason 4 component cancer.

III. To determine the reproducibility of peak lac/pyr, lac/pyr AUC and kPL, urea AUC and urea transfer constant (ktrans) with same-day repeated dose studies. with same-day repeated dose studies.

IV. To compare peak lac/pyr, lac/pyr AUC and kPL, urea AUC, urea transfer constant (ktrans) on MRI with Prostate Imaging-Reporting and Data System (PI-RADS) assessment of multiparametric MRI in predicting regions of cancer versus benign tissue.

EXPLORATORY OBJECTIVES:

I. To correlate histologic markers, including lactate dehydrogenase A (LDHA) expression and activity level, along with Ki-67, MYC, and MCT 1 and 4 expression, with peak intra-tumoral lac/pyr ratio, lactate AUC, and kPL detected using anatomically aligned magnetic resonance (MR) cross-sectional images of the prostate gland.

II. To test for an association between mean intra-tumoral lac/pyr signal and lactate AUC, kPL, urea AUC, and urea transfer constant (ktrans) with adverse clinical and pathologic characteristics including extracapsular extension, positive nodal involvement, and failure to achieve undetectable prostate specific antigen (PSA) nadir following prostatectomy.

OUTLINE:

Participants receive hyperpolarized carbon C 13 pyruvate and urea C-13 intravenously (IV) and undergo MRSI within 12 weeks before undergoing radical prostatectomy. Participants may receive optional second hyperpolarized carbon C 13 pyruvate injection and undergo MRSI within 15-60 minutes after first scan.

After completion of study, participants are followed up at 24 hours.

• Study Type: Interventional
• Enrollment (Estimated): 50
• Phase: Early Phase 1

Contacts and Locations

• Study Contact: Name: Louise Magat; Phone Number: (415) 502-1822; Email: Louise.Magat@ucsf.edu

Study Locations

• United States
  • California
    • San Francisco, California, United States, 94143
      • Recruiting
      • University of California, San Francisco
      • Contact: Louise Magat; Phone Number: 415-502-1822; Email: Louise.Magat@ucsf.edu
      • Contact: Phone Number: 877-827-3222; Email: cancertrials@ucsf.edu
      • Principal Investigator: Ivan de Kouchkovsky, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Biopsy-proven adenocarcinoma of the prostate; biopsy may be performed outside of University of California San Francisco (UCSF), if detailed results of sextant biopsy are available; a minimum of 20 patients out of a planned enrollment of 50 patients must have high-risk disease as defined by primary Gleason score of 4 or 5 on prior prostate biopsy
• Planned radical prostatectomy at UCSF within 12 weeks following protocol MRI/MRSI
• The subject is able and willing to comply with study procedures and provide signed and dated informed consent
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Absolute neutrophil count (ANC) >= 1500 cells/microliter (uL)
• Hemoglobin >= 9.0 mg/dL
• Platelets >= 75,000 cells/uL
• Estimated creatinine clearance >= 50 mL/min (by the Cockcroft Gault equation)
• Bilirubin < 1.5 x upper limit of normal (ULN) (unless Gilbert's is suspected)
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN

Exclusion Criteria:

• Patients who because of general medical or psychiatric condition or physiologic status cannot give valid informed consent
• Patients unwilling or unable to undergo MR imaging, including patients with contra-indications to MRI, such as cardiac pacemakers or non-compatible intracranial vascular clips
• Patients who cannot tolerate or have contra-indications to endorectal coil insertion; for example, patients with a prior abdominoperineal resection of the rectum or latex allergy
• Patients with contra-indications to injection of gadolinium contrast; for example patients with prior documented allergy or those with inadequate renal function
• Metallic hip implant or any other metallic implant or device that distorts local magnetic field and compromises the quality of MR imaging
• Cryosurgery, surgery for prostate cancer, prostatic or pelvic radiotherapy prior to study enrollment; no limit on number of prior prostate biopsies; prior transurethral prostatic resection (TURP) is not allowed
• Current or prior androgen deprivation therapy; a history of use of a 5-alpha reductase inhibitor is allowed, provided it was discontinued at least one month prior to study entry
• Poorly controlled hypertension, with blood pressure at study entry > 160/100; the addition of anti-hypertensives to control blood pressure is allowed for eligibility determination
• Congestive heart failure or New York Heart Association (NYHA) status >= 2
• A history of clinically significant electrocardiography (EKG) abnormalities, including QT prolongation, a family history of prolonged QT interval syndrome, or myocardial infarction (MI) within 6 months of study entry; patients with rate-controlled atrial fibrillation/flutter will be allowed on study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Pre-surgical Prostate Cancer patients; Infusion of co-hyperpolarized 13C pyruvate and undergo and hyperpolarized 13C, 15N urea injection prior to metabolic/perfusion High spatial resolution MRI/1H MRSI staging exam (PROSE) using both a phased-array abdominal coil and an endorectal coil will be performed within 12 weeks of subsequent radical prostatectomy. At least 20 patients will be required to have high risk disease as defined by primary Gleason score of 4 or 5 on prior prostate biopsy

Procedure: Magnetic Resonance Spectroscopic Imaging; Undergo MRSI; Other Names: 1H- Nuclear Magnetic Resonance Spectroscopic Imaging; MRS; MRS Imaging; MRSI; Drug: Hyperpolarized 13C,15N2-urea; Given IV; Other Names: Urea C-13; C13 Urea; Drug: Pyruvate (13C); Given IV; Other Names: Hyperpolarized Pyruvate (13C)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean lactate area under curve (AUC) by Pathological grade	Means and standard deviations for lactate area under curve will be calculated by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)). A One-way ANOVA model will be used to compare lactate area under curve by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)).	Baseline, 1 day
Mean peak intra-tumoral lactate/pyruvate (lac/pyr) ratio by Pathological grade	Means and standard deviations for lactate area under curve will be calculated by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)).	Baseline, 1 day
Mean peak conversion of HP 13C pyruvate to lactate (kPL) by Pathological grade	Means and standard deviations for kPL will be calculated by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)).	Baseline, 1 day
Mean Urea AUC by Pathological grade	Means and standard deviations for Urea AUC will be calculated by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)).	Baseline, 1 day
Mean urea transfer constant (Ktrans) by Pathological grade	Means and standard deviations for Ktrans will be calculated by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)).	Baseline, 1 day

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Optimal cut-off value of lac/pyr area under the curve (AUC)	Receiver-operative-curve analyses will be performed to determine the optimal cut-point of peak lac/pyr AUC values on MRI that accurately detect primary Gleason 4 prostate cancer	Baseline, 1 day
Proportion of participants with Treatment-Related Adverse Events	Assessment of the occurrence of clinically significant changes in safety variables from baseline. Safety endpoints include monitoring for the occurrence of treatment-emergent AEs. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology (Toxicity) Criteria for Adverse Events (CTCAE) version 4.0.	Baseline, 1 day
Compare lactate/pyruvate area under curve (AUC) with Prostate Imaging Reporting and Data System (PI-RADS)	To compare lactate/pyruvate AUC on MRI with PI-RADS assessment of multiparametric MRI in predicting regions of cancer versus benign tissue. Radiologists use the PI-RADS to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious).	Baseline, 1 day
Compare peak lactate/pyruvate with PI-RADS	To compare peak lactate/pyruvate on MRI with PI-RADS assessment of multiparametric MRI in predicting regions of cancer versus benign tissue. Radiologists use the PI-RADS to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious).	Baseline, 1 day
Compare pyruvate to lactate (kPL) with PI-RADS	To compare peak pyruvate to lactate (kPL) on MRI with PI-RADS assessment of multiparametric MRI in predicting regions of cancer versus benign tissue. Radiologists use the PI-RADS to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious).	Baseline, 1 day
Compare urea AUC with PI-RADS	To compare urea AUC on MRI with PI-RADS assessment of multiparametric MRI in predicting regions of cancer versus benign tissue. Radiologists use the PI-RADS to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious).	Baseline, 1 day
Compare urea transfer constant (Ktrans) with PI-RADS	To compare urea ktrans on MRI with PI-RADS assessment of multiparametric MRI in predicting regions of cancer versus benign tissue. Radiologists use the PI-RADS to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious).	Baseline, 1 day
Mean difference in Intra-patient kPL	Intra-patient reproducibility of kPL for patients who undergo repeated dose imaging studies, as descriptively reported using summary statistics.	Baseline, 1 day
Mean difference in Intra-patient Urea AUC	Intra-patient reproducibility of Urea AUC for patients who undergo repeated dose imaging studies, as descriptively reported using summary statistics.	Baseline, 1 day
Mean difference in Intra-patient Urea ktrans	Intra-patient reproducibility of Urea ktrans for patients who undergo repeated dose imaging studies, as descriptively reported using summary statistics	Baseline, 1 day
Optimal cut-off value of peak lactate to pyruvate ratio (lac/pyr)	Receiver-operative-curve analyses will be performed to determine the optimal cut-point of peak lac/pyr AUC on MRI that accurately detect primary Gleason 4 prostate cancer.	Baseline, 1 day
Optimal cut-off value of 13C pyruvate to lactate (kPL) rate	Receiver-operative-curve analyses will be performed to determine the optimal cut-point of kPL on MRI that accurately detect primary Gleason 4 prostate cancer.	Baseline, 1 day
Optimal cut-off value of urea AUC	Receiver-operative-curve analyses will be performed to determine the optimal cut-point of urea AUC on MRI that accurately detect primary Gleason 4 prostate cancer.	Baseline, 1 day
Optimal cut-off value of urea transfer constant (ktrans)	Receiver-operative-curve analyses will be performed to determine the optimal cut-point of urea ktrans on MRI that accurately detect primary Gleason 4 prostate cancer.	Baseline, 1 day
Mean difference in Intra-patient peak lac/pyr	Intra-patient reproducibility of peak lac/pyr for patients who undergo repeated dose imaging studies, as descriptively reported using summary statistics.	Baseline, 1 day
Mean difference in Intra-patient lac/pyr AUC	Intra-patient reproducibility of lac/pyr AUC for patients who undergo repeated dose imaging studies, as descriptively reported using summary statistics.	Baseline, 1 day

Collaborators and Investigators

• Sponsor: Ivan de Kouchkovsky, MD
• Collaborators: National Cancer Institute (NCI); American Cancer Society, Inc.; National Institute for Biomedical Imaging and Bioengineering (NIBIB)
• Investigators: Principal Investigator: Ivan de Kouchkovsky, MD, University of California, San Francisco

Study record dates

Study Major Dates

• Study Start (Actual): March 22, 2016
• Primary Completion (Estimated): December 31, 2024
• Study Completion (Estimated): December 31, 2024

Study Registration Dates

• First Submitted: August 14, 2015
• First Submitted That Met QC Criteria: August 14, 2015
• First Posted (Estimated): August 18, 2015

Study Record Updates

• Last Update Posted (Actual): March 22, 2024
• Last Update Submitted That Met QC Criteria: March 20, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Genital Neoplasms, Male; Prostatic Diseases; Urogenital Diseases; Male Urogenital Diseases; Genital Diseases, Male; Genital Diseases; Prostatic Neoplasms; Anti-Infective Agents, Local; Anti-Infective Agents; Carbamide Peroxide
• Other Study ID Numbers: 15557; R01CA211150 (U.S. NIH Grant/Contract); NCI-2015-02008 (Registry Identifier: NCI Clinical Trials Reporting Program (CTRP)); U01EB026412 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No